Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388536 | 0.91 | MAP2K1 (0.50) | MAP2K1MAP2K2 | |
| SCHEMBL570251 | 0.88 | MAP2K1 (0.71) | MAP2K1ABCB11NQO2MAP2K2 | |
| SCHEMBL29541623 | 0.88 | MAP2K1 (0.71) | MAP2K1ABCB11NQO2MAP2K2 | |
| SCHEMBL393707 | 0.88 | MAP2K1 (0.71) | MAP2K1ABCB11NQO2MAP2K2 | |
| SCHEMBL391890 | 0.83 | MAP2K1 (0.58) | MAP2K1ABCB11NQO2MAP2K2 | |
| SCHEMBL391889 | 0.83 | MAP2K1 (0.58) | MAP2K1ABCB11NQO2MAP2K2 | |
| SCHEMBL391796 | 0.82 | MAP2K1 (0.56) | MAP2K1MAP2K2 | |
| SCHEMBL391795 | 0.82 | MAP2K1 (0.56) | MAP2K1MAP2K2 | |
| SCHEMBL15866541 | 0.82 | MAP2K1 (0.51) | MAP2K1ABCB11NQO2MAP2K2 | |
| SCHEMBL388476 | 0.81 | MAP2K1 (0.69) | MAP2K1ABCB11NQO2MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011095807-A1 | COMBINATIONS OF MEK AND HH INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-11 | — | — | WO | disclosed |
| EP-2231281-A2 | COMBINATION COMPRISING A MEK INHIBITOR AND AN AURORA KINASE INHIBITOR | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| EP-2217234-A2 | COMBINATIONS OF MEK INHIBITORS WITH MTOR INHIBITORS | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20100004247-A1 | COMBINATION COMPRISING A MEK INHIBITOR AND AN AURORA KINASE INHIBITOR 188 | ASTRAZENECA AB (SE) | 2010-01-07 | — | — | US | disclosed |
| WO-2009074827-A2 | COMBINATION COMPRISING A MEK INHIBITOR AND AN AURORA KINASE INHIBITOR 188 | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009050506-A2 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099174-A1 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| WO-2008120004-A1 | COMBINATION OF A MEK- INHIBITOR AND A B-RAF INHIBITOR FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099174-A1 | COMBINATION 059 | MTOR, RICTOR, MAPK9 | MAP2K1 23/4885ABCB11 2351/4885NQO2 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.